Pharmacodynamics Mianserin
mianserin antagonist/inverse agonist (at or sites) of histamine h1 receptor, serotonin 5-ht1d, 5-ht1f, 5-ht2a, 5-ht2b, 5-ht2c, 5-ht3, 5-ht6, , 5-ht7 receptors, , α1- , α2-adrenergic receptors, , inhibits reuptake of norepinephrine well. h1 receptor inverse agonist high affinity, mianserin has strong antihistamine effects (e.g., sedation). conversely, has low affinity muscarinic acetylcholine receptors, , hence lacks anticholinergic properties. mianserin has been found low affinity potentially significant partial agonist of κ-opioid receptor (ki = 1.7 μm; ec50 = 0.53 μm), tricyclic antidepressants (tcas).
blockade of h1 , possibly α1-adrenergic receptors has sedative effects, , antagonism of 5-ht2a , α1-adrenergic receptors inhibits activation of intracellular phospholipase c (plc), seems common target several different classes of antidepressants. antagonizing somatodendritic , presynaptic α2-adrenergic receptors function predominantly inhibitory autoreceptors , heteroreceptors, mianserin disinhibits release of norepinephrine, dopamine, serotonin, , acetylcholine in various areas of brain , body.
along mirtazapine, although lesser extent in comparison, mianserin has been described noradrenergic , specific serotonergic antidepressant (nassa). however, actual evidence in support of label has been regarded poor.
Comments
Post a Comment